Latest News

19

Apr2023

Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations

0  
by webmaster / / Publications
April 19, 2023webmaster

18

Apr2023

Synergistic Antitumor Activity of nab-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts

0  
by webmaster / / Publications
April 18, 2023webmaster

17

Apr2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

0  
by webmaster / / Publications
April 17, 2023webmaster

27

Mar2023

Mohammad Hirmand, MD

0  
by webmaster / / BOD
Dr. Hirmand has served on the Company’s board of directors since March of 2023 and is a co-founder of Avenzo Therapeutics, a privately held oncology company, and serves as its executive vice president and chief medical officer.  Previously, Dr. Hirmand served as executive vice president and chief medical officer of Turning ... Read More
March 27, 2023webmaster

26

Mar2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by candace / / Publications
March 26, 2023candace

26

Mar2023

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

0  
by candace / / Publications
March 26, 2023candace

13

Feb2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by webmaster / / Publications
February 13, 2023webmaster

16

Jan2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by candace / / Publications
January 16, 2023candace

11

Nov2022

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
by production / / Publications
November 11, 2022production

11

Nov2022

Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)

0  
by production / / Publications
November 11, 2022production